Legacy of a magic gene- CCR5- ∆ 32 : From discovery to clinical benefit in a generation.
Level 5 - mechanism / opinion, no new human data
Narrative review and historical overview without new primary data or systematic methodology
PubMed 38457490 · doi:10.1073/pnas.2321907121
What was done
This narrative overview synthesizes the discovery, evolutionary trajectory, and clinical applications of the CCR5-∆32 deletion allele. It reviews the population genetics and proposed historical selective pressures (such as Yersinia pestis), the development of CCR5-targeted entry inhibitors, and outcomes from homozygous CCR5-∆32 stem cell transplants in HIV patients alongside other disease associations.
What was found
The abstract reports that homozygous CCR5-∆32 carriers have near-complete resistance to HIV infection regardless of exposure. Evolutionary models indicate the mutation arose once in the last millennium and reached ~10% frequency in Europeans. Clinically, homozygous CCR5-∆32/∆32 stem cell transplants have produced at least five documented HIV cures. CCR5 deficiency is also noted to influence Staphylococcus aureus infection, stroke recovery, and graft-versus-host disease, while homozygous carriers face an increased risk of encephalomyelitis and death following West Nile virus infection. No comparative effect sizes, relative risks, or confidence intervals are reported in the abstract.
Why it matters
It chronicles the translation of a single genetic discovery into targeted antiviral pharmacology and curative cell therapies for HIV, while highlighting the immunological trade-offs of CCR5 loss of function against other pathogens.
Limits
As a narrative review, it presents no new empirical data, systematic search criteria, or pooled quantitative analyses. The abstract lacks sample sizes, statistical metrics, and detailed cohort definitions for the non-HIV clinical associations described.
Cited by
- supports He Jiankui targeted the CCR5 gene to confer HIV resistance in the gene-edited human embryos.